Whitepapers

Portfolio co-positioning refers to the commercialization of one or more assets by the same company in the same area. Determining which asset is targeted to which patient segment requires a robust and objective process. So, what is the best practice approach to portfolio co-positioning?

Therapies designed to target cancers with specific molecular signatures have reshaped the landscape of oncological drug development.1 As the next generation of tumor-agnostic therapies make their way through clinical trials, we should be asking ourselves what we can do to prepare for the upcoming challenge of reimbursement in this space, and what lessons can be learnt from the experience of existing therapies. Over the coming months we will provide recommendations from our own experience and a review of the experiences of the tropomyosin receptor kinase (TRK) inhibitors (larotrectinib and entrectinib) on how to overcome the common challenges in this space in five short papers. Here, we look at what to consider when developing economic models of tumor-agnostic therapies, with a particular focus on the role of genetic testing in this space.